title: In vivo serial assessment of aortic aneurysm formation in apolipoprotein E-deficient mice via MRI.
abstract: BACKGROUND
  Hyperlipidimic mice administered angiotensin II have been used for the study of abdominal aortic aneurysms (AAAs). The purpose of this study was to examine the use of MRI for studying AAA development and for examining the effects of pharmacological intervention on AAA development in the apolipoprotein E-deficient mouse.
  
  
  RESULTS
  Suprarenal aortic aneurysms were generated in apolipoprotein E-deficient mice administered angiotensin II (1000 ng/kg per min) for up to 28 days. In vivo MRI was performed serially (once weekly) to assess AAA development and rupture. Comparison of AAA size as measured by in vivo and ex vivo MRI resulted in excellent agreement (r=0.96, P<0.0001). In addition, MRI correlated with histology-derived AAA area assessment (in vivo versus histology: r=0.84, P<0.0001; ex vivo versus histology: r=0.89, P<0.0001). In a separate study, angiotensin II-administered apolipoprotein E-deficient mice were treated with doxycycline (broad-based matrix metalloproteinase inhibitor; 30 mg/kg per day for 28 days). MRI was able to noninvasively assess a reduced rate of AAA development (46% versus 71%, P<0.05), a decreased AAA area (2.56 versus 4.02 mm(2), P<0.01), and decreased incidence of rupture (43% versus 100%) in treated versus control animals. Inhibition of aorta matrix metalloproteinase 2/9 activity was observed in the treated animals.
  
  
  CONCLUSIONS
  These results demonstrate the use of MRI to noninvasively and temporally assess AAA development on pharmacological intervention in this preclinical cardiovascular disease model.
authors.affiliation: Cardiovascular and Urogenital Center of Excellence for Drug Discovery, GlaxoSmithKline, King of Prussia, PA 19406, USA.
authors.forename: Gregory H
authors.initials: GH
authors.lastname: Turner
authors.forename: Alan R
authors.initials: AR
authors.lastname: Olzinski
authors.forename: Roberta E
authors.initials: RE
authors.lastname: Bernard
authors.forename: Karpagam
authors.initials: K
authors.lastname: Aravindhan
authors.forename: Heather W
authors.initials: HW
authors.lastname: Karr
authors.forename: Rosanna C
authors.initials: RC
authors.lastname: Mirabile
authors.forename: Robert N
authors.initials: RN
authors.lastname: Willette
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Gough
authors.forename: Beat M
authors.initials: BM
authors.lastname: Jucker
mesh_terms: D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D001012:Aorta, Abdominal / Q000473:pathology; D017544:Aortic Aneurysm, Abdominal / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology; D001057:Apolipoproteins E / Q000172:deficiency*; D004318:Doxycycline / Q000494:pharmacology; D008279:Magnetic Resonance Imaging; D008297:Male; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout
chemical_list: D001057:Apolipoproteins E; D061965:Matrix Metalloproteinase Inhibitors; D000804:Angiotensin II; D020782:Matrix Metalloproteinases; D004318:Doxycycline